Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Fundraising

Waters Corporation

Waters Corporation Raises $12B in Public

34 Maple Street, Milford, MA 01757January 1, 20242 min read
Employees
7500+

Waters Corporation Raises $12B in Public


Waters Corporation has successfully raised $12B in a Public at a $14B valuation led by Public.


Company Overview


Waters Corporation is a Life Sciences company headquartered in 34 Maple Street, Milford, MA 01757, founded in 1958 with 7500+ employees.


Analytical instruments manufacturer


Fundraising Details


  • Amount Raised: $12B
  • Round Type: Public
  • Valuation: $14B
  • Date: 2024-01-01
  • Investors: Public

About Waters Corporation


Analytical instruments manufacturer The company is positioned in the Life Sciences sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 34 Maple Street, Milford, MA 01757
  • Founded: 1958
  • Team Size: 7500+
  • Industry: Life Sciences

What This Means


This funding round demonstrates strong investor confidence in Waters Corporation's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Life Sciences sector continues to attract significant investment as companies innovate to meet evolving market demands. Waters Corporation's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $14B valuation marks an important milestone for Waters Corporation, positioning the company among notable players in the Life Sciences industry.


Looking Ahead


With this new capital, Waters Corporation is well-positioned to execute on its growth strategy and continue building innovative solutions in the Life Sciences space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-01. For more information about Waters Corporation, visit their headquarters at 34 Maple Street, Milford, MA 01757.

Company Info

Headquarters
34 Maple Street, Milford, MA 01757
Founded
1958
Team Size
7500+

Topics

Fundraising(2912)Public(771)Life SciencesWaters Corporation

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min readβ€’$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free